Neuro-Oncology News

The FDA granted fast track designation to several agents under investigation for the treatment of patients with certain solid tumors or hematologic malignancies.

The FDA granted fast track and orphan drug designations to PTC596 for treatment of leiomyosarcoma, according to the agent’s manufacturer.

A personalized cancer vaccine improved PFS compared with historical outcomes with standard-of-care treatment for patients with newly diagnosed glioblastoma, according to phase 2 study results.

Stereotactic body radiation therapy appeared more effective than conventional radiation in alleviating pain from spinal tumors, according to a Canadian Cancer Trials Group phase 2/phase 3 study presented at the virtual ASTRO Annual Meeting.

Stereotactic radiosurgery conferred equivalent OS as whole-brain radiation but with less cognitive decline in patients with four or more nonmelanoma brain metastases, according to study results presented at the virtual ASTRO Annual Meeting.

The FDA approved the FoundationOne CDx test to help identify certain neurotrophic receptor tyrosine kinase gene fusions in patients with solid tumors eligible for treatment with larotrectinib, according to a press release from the agency.

Local hypofractionated stereotactic radiotherapy to the resection cavity demonstrated a favorable risk-benefit profile among patients with brain metastases, according to results of an international, multicenter cohort study.

In this video from the Annual Meeting of the American Neurological Association, David Gutmann, MD, PhD, FAAN, discusses the plenary session he co-chaired with Steven Small, MD, PhD, on microenvironment control of brain tumor pathogenesis.

City of Hope announced it has reached an agreement with Australia-based biotech Chimeric Therapeutics.

The FDA granted orphan drug designation to rhenium nanoliposomes for the treatment of patients with recurrent glioblastoma, according to a manufacturer-issued press release.